Inventiva (NASDAQ:IVA) Reaches New 1-Year High - What's Next?

Key Points

• Inventiva's share price reached a new 52-week high of $5.38, marking a significant rise from its previous close of $4.59, with a trading volume of 5,394 shares.
• Piper Sandler has initiated coverage on Inventiva with an "overweight" rating and a target price of $26.00, contributing to a current average rating of "Moderate Buy" from analysts.
• Institutional investors now own 19.06% of Inventiva's stock, with Creative Planning acquiring a new stake of 10,000 shares valued at approximately $32,000 during the second quarter.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) shares hit a new 52-week high on Wednesday . The stock traded as high as $5.38 and last traded at $5.34, with a volume of 5394 shares. The stock had previously closed at $4.59.

Analyst Ratings Changes

Separately, Piper Sandler began coverage on shares of Inventiva in a research note on Wednesday, August 27th. They set an "overweight" rating and a $26.00 target price on the stock. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, Inventiva currently has a consensus rating of "Moderate Buy" and an average price target of $13.00.

Inventiva Trading Down 2.5%

The firm's 50 day moving average is $3.65 and its two-hundred day moving average is $3.37.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Inventiva stock. Wealth Enhancement Advisory Services LLC boosted its position in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) by 54.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,558 shares of the company's stock after acquiring an additional 5,843 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Inventiva were worth $50,000 as of its most recent SEC filing. Institutional investors and hedge funds own 19.06% of the company's stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.